1Nordlinger B, Guiguet M, Vaillant JC,et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Fran~aise de Chirurgie. Cancer, 1996,77 (7) :1254- 1262.
2Karapetis CS, Khambata-Ford S, Jonker D J, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med, 2008, 359 ( 17 ) : 1757-1765.
3Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic: colorectal cancer. J Clin Oncol, 2008, 26 (10) : 1626-1634.
4Peeters M, Price TJ, Cervantes A, et al. Randomized phase IH study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol, 2010, 28(51 ) :4706-4713.
5Bokemeyer C, Bondarenko I, Hartmann JT, et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first- line treatment for metastatic colorectal cancer: the OPUS study. Ann Oncol, 2011, 22(7) :1535-1546.
6NCCN. Clinical practice guidelines in oncology: colon cancer. Version 3. 2012 [ EB/OL]. [ 2012-07-16 ]. http://www, necn. org/professionals/physician_gls/pdf/colon, pdf.
7Der C J, Cooper GM. Altered gene products are associated with activation of cellular Kras genes in human lung and colon carcinomas. Cell, 1983, 32( 1 ) :201-208.
8Gideon P, John J, Frech M, et al. Mutational and kinetic: analyses of the GTPase-activating protein (GAP)-p21 interaction: the C-terminal domain of GAP is not sufficient for full activity. Mol Cell Biol, 1992,12 (5) :2050-2056.
9Rajagopalan H, Bardelli A, Lengauer C, et al. Tumorigenesis : RAF/RAS oncogenes and mismatch-repair status. Nature, 2002, 418(6901 ) :934.
10Samowitz WS, Curtin K, Schaffer D,et al. Relationship of K-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Biomarkers Prey, 2000,9( 11 ) :1193-1197.
1Yoshito Komatsu,Takayuki Yoshino,Kentaro Yamazaki,Satoshi Yuki,Nozomu Machida,Takahide Sasaki,Ichinosuke Hyodo,Yutaka Yachi,Hiroshi Onuma,Atsushi Ohtsu.Phase 1 study of efatutazone, a novel oral peroxisome proliferator-activated receptor gamma agonist, in combination with FOLFIRI as second-line therapy in patients with metastatic colorectal cancer[J]. Investigational New Drugs . 2014 (3)
2Pavithra Shyamsunder,Prasanna Vidyasekar,Akshay Ranjan Shukla,Sheila Mohan,Rama Shanker Verma.Lowered expression levels of a tumor suppressor gene — Caveolin-1 within dysregulated gene networks of Fanconi anemia[J]. Gene . 2013
3Muramatsu S,Tanaka S,Mogushi K,Adikrisna R,Aihara A,Ban D,Ochiai T,Irie T,Kudo A,Nakamura N,Nakayama K,Tanaka H,Yamaoka S,Arii S.Visualization of stem cell features in human hepatocellular carcinoma reveals in vivo significance of tumor-host interaction and clinical course. Hepatology . 2013
